Pacific Biosciences of California PACB EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Pacific Biosciences of California’s reported figures.
Based on trailing twelve months.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's EBITDA margin?
- Pacific Biosciences of California (PACB) reported EBITDA margin of -74.5% in Q1 2026.
- How has Pacific Biosciences of California's EBITDA margin changed year-over-year?
- Pacific Biosciences of California's EBITDA margin increased by 72.9% year-over-year, from -275.2% to -74.5%.
- What is the long-term trend for Pacific Biosciences of California's EBITDA margin?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's EBITDA margin has grown at a -2.4% compound annual growth rate (CAGR), from -121.1% to -107.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.